Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the standard of care and the potential of NAYZILAM (midazolam), a nasal spray able to return patients experiencing seizure clusters back to baseline function within 90 minutes

Ticker(s): UCB

Who's the expert?

Institution: Mecklenburg Neurology

Epilepsy Fellowship trained in Epilepsy and completed an internship in Internal Medicine; residency in Adult Neurology
Manages 100 patients with MA

Interview Goal

This interview will focus on the post hoc analysis published by Epilepsy & Behavior regarding the Phase 3 open-label extension study of NAYZILAM, which showed the estimated median time to RTFBF, regardless of treatment with one or two doses, was 90 minutes.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.